Sling Therapeutics is a clinical-stage biopharmaceutical company in Ann Arbor, Michigan developing linsitinib, the first and only late-stage oral small-molecule IGF-1R inhibitor for the treatment of thyroid eye disease (TED).
First patients dosed in the global Phase 3 trial of linsitinib in thyroid eye disease
$123M Series C financing closed to fund Phase 3 development
Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting linsitinib for an eye disease that has attracted lots of VC and pharma attention in recent years.
President and Chief Executive Officer
Chairman
Chief Commercial Officer
No active job listings. Check back later.